soul trial oral semaglutide cardiovascular outcomes trial results trials: a paradigm shift in the current management of type 2 diabetes | Cardiovascular Diabetology soul trial oral semaglutide cardiovascular

6 Pfizer R&D UK Ltd., Tadworth, UK The Journal of Headache and Pain 2026 , 27(S1): P159 Objective To assess rimegepant (Rim) for acute treatment of migraine in adults unsuitable for triptans (NCT05509400)

Introduction Weight gain during perimenopause and menopause can feel different from earlier weight changes, especially when it concentrates around the abdomen

Medications targeting GIP and GLP-1 pathways improve glycemic control by enhancing glucose-dependent insulin secretion, suppressing inappropriate glucagon release, and slowing gastric emptying

Since the burning of fat is a major source of muscular energy, deficiencies in L-Carnitine are manifested as low energy levels and muscular weakness